1 - 25 of
38
results
for author:"Weber B.L."
in Literature Citations
| Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell lines. Greshock J., Nathanson K., Medina A., Ward M.R., Herlyn M., Weber B.L., Zaks T.Z. Genes Chromosomes Cancer 48:419-428(2009) · Mapped (3) |
| A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Flaherty K.T., Schiller J., Schuchter L.M., Liu G., Tuveson D.A., Redlinger M., Lathia C., Xia C., Petrenciuc O., Hingorani S.R. et al. Clin. Cancer Res. 14:4836-4842(2008) · Mapped (3) |
| Network modeling links breast cancer susceptibility and centrosome dysfunction. Pujana M.A., Han J.D., Starita L.M., Stevens K.N., Tewari M., Ahn J.S., Rennert G., Moreno V., Kirchhoff T., Gold B. et al. Nat. Genet. 39:1338-1349(2007) · Mapped (8) |
| Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States. Tchou J., Ward M.R., Volpe P., Palma M.D., Medina C.A., Sargen M., Sonnad S.S., Godwin A.K., Daly M., Winchester D.J. et al. Clin. Breast Cancer 7:627-633(2007) · Mapped (42) |
| Patterns of somatic mutation in human cancer genomes. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C. et al. Nature 446:153-158(2007) · UniProtKB (453) |
| A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers. Thompson D., Seal S., Schutte M., McGuffog L., Barfoot R., Renwick A., Eeles R., Sodha N., Houlston R., Shanley S. et al. Cancer Epidemiol. Biomarkers Prev. 15:2542-2545(2006) · Mapped (4) |
| Clinical management of BRCA1 and BRCA2 mutation carriers. Domchek S.M., Weber B.L. Oncogene 25:5825-5831(2006) · Mapped (42) |
| Characterization of BRCA1 and BRCA2 mutations in a large United States sample. Chen S., Iversen E.S., Friebel T., Finkelstein D., Weber B.L., Eisen A., Peterson L.E., Schildkraut J.M., Isaacs C., Peshkin B.N. et al. J. Clin. Oncol. 24:863-871(2006) · Mapped (42) |
| The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. Colilla S., Kantoff P.W., Neuhausen S.L., Godwin A.K., Daly M.B., Narod S.A., Garber J.E., Lynch H.T., Brown M., Weber B.L. et al. Carcinogenesis 27:599-605(2006) · Mapped (8) |
| Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth. Zhang L., Yang N., Huang J., Buckanovich R.J., Liang S., Barchetti A., Vezzani C., O'Brien-Jenkins A., Wang J., Ward M.R. et al. |
| Lung cancer: intragenic ERBB2 kinase mutations in tumours. Stephens P., Hunter C., Bignell G., Edkins S., Davies H., Teague J., Stevens C., O'Meara S., Smith R., Parker A. et al. Nature 431:525-526(2004) · Mapped (8) |
| Characterization of two novel BRCA1 germ-line mutations involving splice donor sites. Brose M.S., Volpe P., Paul K., Stopfer J.E., Colligon T.A., Calzone K.A., Weber B.L. Genet. Test. 8:133-138(2004) · Mapped (32) |
| SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. Tsavachidou D., Coleman M.L., Athanasiadis G., Li S., Licht J.D., Olson M.F., Weber B.L. Cancer Res. 64:5556-5559(2004) · Mapped (5) |
| Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Jernstrom H., Lubinski J., Lynch H.T., Ghadirian P., Neuhausen S., Isaacs C., Weber B.L., Horsman D., Rosen B., Foulkes W.D. et al. J. Natl. Cancer Inst. 96:1094-1098(2004) · Mapped (42) |
| Absence of BRAF mutations in UV-protected mucosal melanomas. Edwards R.H., Ward M.R., Wu H., Medina C.A., Brose M.S., Volpe P., Nussen-Lee S., Haupt H.M., Martin A.M., Herlyn M. et al. J. Med. Genet. 41:270-272(2004) · Mapped (3) |
| Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Foulkes W.D., Metcalfe K., Sun P., Hanna W.M., Lynch H.T., Ghadirian P., Tung N., Olopade O.I., Weber B.L., McLennan J. et al. Clin. Cancer Res. 10:2029-2034(2004) · Mapped (42) |
| MYC is amplified in BRCA1-associated breast cancers. Grushko T.A., Dignam J.J., Das S., Blackwood A.M., Perou C.M., Ridderstrale K.K., Anderson K.N., Wei M.J., Adams A.J., Hagos F.G. et al. Clin. Cancer Res. 10:499-507(2004) · Mapped (40) |
| Population frequencies of single nucleotide polymorphisms (SNPs) in immuno-modulatory genes. Martin A.M., Athanasiadis G., Greshock J.D., Fisher J., Lux M.P., Calzone K., Rebbeck T.R., Weber B.L. Hum. Hered. 55:171-178(2003) · Mapped (75) |
| Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Schutte M., Seal S., Barfoot R., Meijers-Heijboer H., Wasielewski M., Evans D.G., Eccles D., Meijers C., Lohman F., Klijn J. et al. Am. J. Hum. Genet. 72:1023-1028(2003) · UniProtKB (1) · Mapped (3) |
| Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. Brose M.S., Rebbeck T.R., Calzone K.A., Stopfer J.E., Nathanson K.L., Weber B.L. J. Natl. Cancer Inst. 94:1365-1372(2002) · Mapped (32) |
| Mutations of the BRAF gene in human cancer. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W. et al. |
| CGH-targeted linkage analysis reveals a possible BRCA1 modifier locus on chromosome 5q. Nathanson K.L., Shugart Y.Y., Omaruddin R., Szabo C., Goldgar D., Rebbeck T.R., Weber B.L. Hum. Mol. Genet. 11:1327-1332(2002) · Mapped (32) |
| BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. Shih H.A., Couch F.J., Nathanson K.L., Blackwood M.A., Rebbeck T.R., Armstrong K.A., Calzone K., Stopfer J., Seal S., Stratton M.R. et al. J. Clin. Oncol. 20:994-999(2002) · Mapped (42) |
| Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Chen J., Silver D.P., Walpita D., Cantor S.B., Gazdar A.F., Tomlinson G., Couch F.J., Weber B.L., Ashley T., Livingston D.M. et al. Mol. Cell 2:317-328(1998) · Mapped (3) |
| Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening. Andersen T.I., Eiken H.G., Couch F., Kaada G., Skrede M., Johnsen H., Aloysius T.A., Tveit K.M., Tranebjaerg L., Doerum A. et al. Hum. Mutat. 11:166-174(1998) · UniProtKB (1) |
